+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Plaque Psoriasis Treatment Market - Global Forecast Report 2023-2031

  • PDF Icon

    Report

  • 160 Pages
  • April 2023
  • Region: Global
  • Expert Market Research
  • ID: 5780662
The global plaque psoriasis treatment market is expected to grow significantly during the forecast period of 2023-2031. The increasing prevalence of plaque psoriasis worldwide, coupled with the growing investment in research and development activities, is driving the growth of the market. The global plaque psoriasis disease prevalence is likely to grow at a CAGR of 3% during the forecast period.

Plaque Psoriasis Treatment Market: Introduction

The global plaque psoriasis treatment market report provides an in-depth analysis of the market and its segments. Plaque psoriasis is a chronic autoimmune disorder that affects the skin, characterized by red, scaly patches that can be painful and itchy. The lack of effective treatments for plaque psoriasis has been a major challenge for healthcare providers and researchers worldwide. The report covers the market for plaque psoriasis treatment and provides a detailed analysis of the market size, growth, and trends.

The plaque psoriasis treatment market is expected to witness significant advancements in the coming years. The development of novel therapies, such as biologics and small molecules, and the increasing focus on personalized medicine are likely to drive the growth of the market. Additionally, the expansion of healthcare infrastructure in emerging economies and the increasing demand for advanced diagnostic tools and treatment options are expected to create lucrative opportunities for the market players.

Moreover, the growing adoption of telemedicine and digital health technologies may provide new avenues for the management and treatment of plaque psoriasis, potentially improving patient outcomes and reducing healthcare costs. As a result, the global plaque psoriasis treatment market is expected to continue its growth trajectory throughout the forecast period, offering numerous opportunities for key players and investors in the industry.

Plaque Psoriasis Epidemiology

The global epidemiology of plaque psoriasis varies based on factors such as geographic location, ethnicity, and age. The prevalence of plaque psoriasis ranges from 1% to 3% of the population worldwide. The disease affects both genders and can occur at any age, with the most common age of onset being between 15 and 35 years.

The plaque psoriasis treatment market is highly competitive, with numerous small and mid-sized companies operating in the market. The lack of effective treatments for plaque psoriasis has led to the emergence of many companies focusing on the development of innovative therapies for this disease.

Plaque Psoriasis Treatment Market Segmentations

The market can be categorised into diagnosis method, treatment type, therapy type, route of administration, drug type, population type, treatment channel, end user, distribution channel, and region.

Market Breakup by Diagnosis Method

  • Blood Tests
  • Skin Prick Test
  • Patch Test
  • Biopsy
  • Others

Plaque Psoriasis Treatment Market Breakup by Treatment Type

Biologics Drugs

  • Apremilast
  • Atanercept
  • Infliximab
  • Adalimumab
  • Ustekinumab
  • Secukinumab
  • Ixekizumab
  • Guselkumab
  • Tildrakizumab
  • Certolizumab
  • Others

Systemic Drugs

  • Methotrexate
  • Soriatane
  • Otezla
  • Sotyktu
  • Cyclosporin
  • Others

Phototherapy

  • Ultraviolet B (UVB)

Topical Drugs

  • Calcipotriene
  • Tazarotene
  • Calcineurin Inhibitors
  • Roflumilast
  • Salicylic Acid
  • Others

Market Breakup by Therapy Type

  • Monotherapy
  • Combination Therapy

Market Breakup by Route of Administration

  • Oral
  • Tablets
  • Capsules
  • Parentals
  • Intravenous
  • Intramuscular
  • Topicals
  • Others

Plaque Psoriasis Treatment Market Breakup by Drug Type

  • Over the Counter
  • Prescription
  • Branded
  • Generics

Market Breakup by Population Type

  • Children
  • Adults
  • Male
  • Female
  • Geriatrics
  • Male
  • Female

Market Breakup by Treatment Channel

  • Public
  • Private

Market Breakup by End User

  • Hospitals
  • Specialty Clinics
  • Homecare Settings
  • Others

Market Breakup by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Market Breakup by Region

North America

  • United States of America
  • Canada

Europe

  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Plaque Psoriasis Treatment Market Scenario

North America dominates the rare diseases treatment market, followed by Europe and the Asia Pacific. The high prevalence of rare diseases in North America, coupled with the favourable reimbursement policies, is driving the growth of the market in the region. Europe is also a significant market for rare diseases treatment, with the presence of key players and increasing investment in research and development activities. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing awareness about rare diseases and the rising healthcare expenditure in the region.

The market is highly fragmented, with numerous small and mid-sized companies operating in the market. The lack of effective treatments for rare diseases has led to the emergence of many companies focusing on the development of innovative therapies for these diseases. The market for biological drugs is expected to grow significantly during the forecast period, driven by the increasing adoption of innovative therapies such as gene therapy and cell therapy.

Key Players in the Global Plaque Psoriasis Treatment Market

The report gives an in-depth analysis of the key players involved in the plaque psoriasis treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
  • Pfizer Inc
  • Abbvie Inc
  • Novartis AG
  • Amgen Inc
  • Boehringer Ingelheim International GmbH
  • Merck & Co Inc
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceuticals Industries Ltd
  • AstraZeneca
  • Ampio Pharmaceuticals Inc
  • Eli Lilly and Company
  • Novartis International AG
  • Sun Pharmaceuticals Industries Ltd
  • Stiefel Laboratories
  • UCB S.A
  • LEO Pharma
  • Cipla Inc
  • Rowan Bioceuticals
  • Glenmark Pharmaceuticals
  • Win-Medicare Pvt. Ltd
  • Sanofi S.A

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Plaque Psoriasis Diseases Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Plaque Psoriasis Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Plaque Psoriasis Epidemiology (2016-2031)
5.3 Europe Plaque Psoriasis Epidemiology (2016-2031)
5.4 Asia-Pacific Plaque Psoriasis Epidemiology (2016-2031)
5.5 Latin America Plaque Psoriasis Epidemiology (2016-2031)
5.6 Middle East & Africa Plaque Psoriasis Epidemiology (2016-2031)
6 Global Plaque Psoriasis Treatment Market Overview
6.1 Global Plaque Psoriasis Treatment Market Historical Value (2016-2022)
6.2 Global Plaque Psoriasis Treatment Market Forecast Value (2023-2031)
7 Global Plaque Psoriasis Treatment Market Landscape
7.1 Plaque Psoriasis Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
8 Plaque Psoriasis Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Plaque Psoriasis Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Plaque Psoriasis Treatment Market Segmentation
11.1 Global Plaque Psoriasis Treatment Market by Diagnosis Method
11.1.1 Market Overview
11.1.2 Blood Tests
11.1.3 Skin Prick Test
11.1.4 Patch Test
11.1.5 Biopsy
11.1.6 Others
11.2 Global Plaque Psoriasis Treatment Market by Treatment Type
11.2.1 Market Overview
11.2.2 Biologics Drugs
11.2.2.1 Apremilast
11.2.2.2 Atanercept
11.2.2.3 Infliximab
11.2.2.4 Adalimumab
11.2.2.5 Ustekinumab
11.2.2.6 Secukinumab
11.2.2.7 Ixekizumab
11.2.2.8 Guselkumab
11.2.2.9 Tildrakizumab
11.2.2.10 Certolizumab
11.2.2.11 Others
11.2.3 Systemic Drugs
11.2.3.1 Methotrexate
11.2.3.2 Soriatane
11.2.3.3 Otezla
11.2.3.4 Sotyktu
11.2.3.5 Cyclosporin
11.2.3.6 Others
11.2.4 Phototherapy
11.2.4.1 Ultraviolet B (UVB)
11.2.5 Topical Drugs
11.2.5.1 Calcipotriene
11.2.5.2 Tazarotene
11.2.5.3 Calcineurin inhibitors
11.2.5.4 Roflumilast
11.2.5.5 Salicylic acid
11.2.5.6 Others
11.2.6 Others
11.3 Global Plaque Psoriasis Treatment Market by Therapy Type
11.3.1 Market Overview
11.3.2 Monotherapy
11.3.3 Combination Therapy
11.4 Global Plaque Psoriasis Treatment Market by Route of Administration
11.4.1 Market Overview
11.4.2 Oral
11.4.2.1 Tablets
11.4.2.2 Capsules
11.4.3 Parentals
11.4.3.1 Intravenous
11.4.3.2 Intramuscular
11.4.4 Topicals
11.4.5 Others
11.5 Global Plaque Psoriasis Treatment Market by Drug Type
11.5.1 Market Overview
11.5.2 Over the Counter
11.5.3 Prescription
11.5.3.1 Branded
11.5.3.2 Generics
11.6 Global Plaque Psoriasis Treatment Market by Population Type
11.6.1 Market Overview
11.6.2 Children
11.6.3 Adults
11.6.3.1 Male
11.6.3.2 Female
11.6.4 Geriatrics
11.6.4.1 Male
11.6.4.2 Female
11.7 Global Plaque Psoriasis Treatment Market by Treatment Channel
11.7.1 Market Overview
11.7.2 Public
11.7.3 Private
11.8 Global Plaque Psoriasis Treatment Market by End User
11.8.1 Market Overview
11.8.2 Hospitals
11.8.3 Specialty Clinics
11.8.4 Homecare Settings
11.8.5 Others
11.9 Global Plaque Psoriasis Treatment Market by Distribution Channel
11.9.1 Market Overview
11.9.2 Hospital Pharmacy
11.9.3 Retail Pharmacy
11.9.4 Online Pharmacy
11.9.5 Others
11.10 Global Plaque Psoriasis Treatment Market by Region
11.10.1 Market Overview
11.10.2 North America
11.10.3 Europe
11.10.4 Asia Pacific
11.10.5 Latin America
11.10.6 Middle East and Africa
12 North America Plaque Psoriasis Treatment Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Plaque Psoriasis Treatment Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Plaque Psoriasis Treatment Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Plaque Psoriasis Treatment Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Plaque Psoriasis Treatment Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Pfizer Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Abbvie Inc.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Novartis AG
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Amgen Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Boehringer Ingelheim International GmbH.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Merck & Co Inc.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Sun Pharmaceutical Industries Ltd.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Teva Pharmaceuticals Industries Ltd.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 AstraZeneca
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Ampio Pharmaceuticals Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Eli Lilly and Company
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Novartis International AG
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 Sun Pharmaceuticals Industries Ltd.
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
23.14 Stiefel Laboratories
23.14.1 Financial Analysis
23.14.2 Product Portfolio
23.14.3 Demographic Reach and Achievements
23.14.4 Mergers and Acquisitions
23.14.5 Certifications
23.15 UCB S.A.
23.15.1 Financial Analysis
23.15.2 Product Portfolio
23.15.3 Demographic Reach and Achievements
23.15.4 Mergers and Acquisitions
23.15.5 Certifications
23.16 LEO Pharma
23.16.1 Financial Analysis
23.16.2 Product Portfolio
23.16.3 Demographic Reach and Achievements
23.16.4 Mergers and Acquisitions
23.16.5 Certifications
23.17 Cipla Inc.
23.17.1 Financial Analysis
23.17.2 Product Portfolio
23.17.3 Demographic Reach and Achievements
23.17.4 Mergers and Acquisitions
23.17.5 Certifications
23.18 Rowan Bioceuticals
23.18.1 Financial Analysis
23.18.2 Product Portfolio
23.18.3 Demographic Reach and Achievements
23.18.4 Mergers and Acquisitions
23.18.5 Certifications
23.19 Glenmark Pharmaceuticals
23.19.1 Financial Analysis
23.19.2 Product Portfolio
23.19.3 Demographic Reach and Achievements
23.19.4 Mergers and Acquisitions
23.19.5 Certifications
23.20 Win-Medicare Pvt. Ltd.
23.20.1 Financial Analysis
23.20.2 Product Portfolio
23.20.3 Demographic Reach and Achievements
23.20.4 Mergers and Acquisitions
23.20.5 Certifications
23.21 Sanofi S.A.
23.21.1 Financial Analysis
23.21.2 Product Portfolio
23.21.3 Demographic Reach and Achievements
23.21.4 Mergers and Acquisitions
23.21.5 Certifications
24 Plaque Psoriasis Treatment Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

Companies Mentioned

  • Pfizer Inc.
  • Abbvie Inc.
  • Novartis AG
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH.
  • Merck & Co Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • AstraZeneca
  • Ampio Pharmaceuticals Inc.
  • Eli Lilly and Company
  • Novartis International AG
  • Sun Pharmaceuticals Industries Ltd.
  • Stiefel Laboratories
  • UCB S.A.
  • LEO Pharma
  • Cipla Inc.
  • Rowan Bioceuticals
  • Glenmark Pharmaceuticals
  • Win-Medicare Pvt. Ltd.
  • Sanofi S.A.

Methodology

Loading
LOADING...

Table Information